Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Mafenide acetate

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Mafenide acetate used for?
The FDA-approved label (Sulfamylon, Rising Pharma Holdings, Inc., July 3, 2023) says: “SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Mafenide acetate have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Mafenide acetate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Mafenide acetate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Mafenide acetate?
1 company lists prescription products of Mafenide acetate in the FDA NDC Directory, including Rising Pharma Holdings, Inc..

What Mafenide acetate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns.

— FDA label: Sulfamylon, Rising Pharma Holdings, Inc., effective July 3, 2023. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsCream
RouteTopical
Prescription products1 in the FDA NDC Directory
Brand namesSulfamylon

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Mafenide acetate, by strength and form
Strength and formGeneric or brandPharmacies pay
mafenide acetate 8.5%
cream
Brand: Sulfamylon $1.23 per gram

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA016763
SULFAMYLON
RisingJanuary 24, 1969 18, latest December 13, 2002
2002: Manufacturing (CMC) · 2000: Manufacturing (CMC) · 1999: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)201185, 311406
SPL set ID of the quoted label008eaa23-8f19-4e39-85ff-540c1c834a9e
FDA labels (SPL)1
FDA applicationsNDA016763
Active ingredients (FDA)MAFENIDE ACETATE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Sulfamylon, Rising Pharma Holdings, Inc., effective July 3, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers